MedTrace Logo

PCI vs. CABG in UPLM-ISR

NCT04968977 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 305

Last updated 2021-07-20

No results posted yet for this study

Summary

Left main (LM) coronary artery disease is associated with high morbidity and mortality owing to the large myocardial territory at risk for ischemia. Evidence from randomized controlled trials supports that percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for LM disease is an acceptable treatment strategy compared with coronary artery bypass graft surgery in patients with low or intermediate anatomic complexity. However in-stent restenosis (ISR) after DES in LM disease is still occurring with an incidence of 9,7%. Studies comparing the percutaneous coronary intervention with coronary artery bypass grafting (CABG) in the treatment of in-stent restenosis in unprotected left main have been scarce. While surgical revascularization is considered to be the standard treatment for this kind of stent failure, owing to a high risk of perioperative morbidity and mortality, the restoration of flow with PCI may be a reliable alternative. Additionally, it is not clear whether re-PCI is safe in these patients. Therefore, the purpose of the present study was to compare long-term outcomes following PCI or CABG for UPLM-ISR disease.

Conditions

  • Restenosis, Coronary
  • Left Main Coronary Artery Disease
  • PTCA Left Main Artery Complications

Interventions

PROCEDURE

PCI vs. CABG

PCI vs. CABG

Sponsors & Collaborators

  • Medical University of Silesia

    lead OTHER

Eligibility

Sex
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-01
Primary Completion
2021-06-01
Completion
2021-06-01

Countries

  • Italy
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04968977 on ClinicalTrials.gov